GAINESVILLE, Fla., and CAMBRIDGE, Mass., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced its participation in upcoming conferences.
- Genetic Rx — Boston, Mass. (December 8, 2016)
AGTC President & CEO Sue Washer will be moderating a panel discussion entitled “Manufacturing and Commercialization: Strategies for Success” from 11:45am – 12:15pm ET. The event will take place at Harvard Medical School and will bring together academics, key industry leaders and investors to discuss the emergence of new genetic medicines as well as the treatment of patients with rare genetic diseases.
- BMO Capital Markets Prescriptions for Success Healthcare Conference – New York, N.Y. (December 14, 2016)
Sue Washer will provide a company presentation at 3:20pm ET. Ms. Washer will discuss key corporate milestones in addition to reviewing AGTC's clinical pipeline. A live audio webcast of the presentation can be accessible by visiting ir.agtc.com/events.cfm. A replay will be available on the company’s website following the event.
About AGTC
AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology. AGTC's lead product candidates are designed to treat inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments.
AGTC's product pipeline includes six named ophthalmology development programs across five targets (X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), achromatopsia, wet age-related macular degeneration and blue cone monochromacy), two non-ophthalmology programs (alpha-1 antitrypsin deficiency and adrenoleukodystrophy) and AGTC is continuing to develop early research studies in additional indications. The company is also exploring genetic defects in cells in the inner ear that lead to deafness and expects to advance several product candidates into development within the next few years. AGTC employs a highly targeted approach to selecting and designing its product candidates, choosing to develop therapies for indications having high unmet medical need, clinical feasibility and commercial potential. AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as, expertise in the formulation, manufacture and physical delivery of gene therapy products.